Abstract
Idiopathic pulmonary fibrosis (IPF) is an important, and devastating, interstitial lung disease. It has a median mortality of only 3 years, worse than many cancers, and its incidence continues to rise. In this article, an overview of key developments in our understanding and clinical management of IPF will be provided.
MeSH terms
-
Administration, Oral
-
Adrenal Cortex Hormones / administration & dosage
-
Anti-Inflammatory Agents / administration & dosage
-
Combined Modality Therapy
-
Cortisone / administration & dosage
-
Humans
-
Prognosis
-
Pulmonary Fibrosis / diagnosis
-
Pulmonary Fibrosis / epidemiology
-
Pulmonary Fibrosis / therapy*
Substances
-
Adrenal Cortex Hormones
-
Anti-Inflammatory Agents
-
Cortisone